Corporation will use the $200,000 award to improve activity of antiviral antibodies.

Profectus BioSciences won approximately $200,000 through a phase 1 SBIR grant from the NIAID. The company will use the funding to advance development of anti-HIV antibodies based on its AIM (antiviral immune modulation) therapy technology. The work will be conducted in collaboration with the Institute of Human Virology at the University of Maryland.

AIM uses immune modulation drugs such as Rapamycin to improve the activity of antiviral antibodies, the company explains. “We believe that AIM therapy combinations can improve patient outcomes by providing less frequent dosing with fewer side effects and by slowing or preventing drug-resistant viruses that can drive treatment failure,” says Joseph F. Berardino, chairman and CEO. “Such an approach may also provide treatment options that permit intervention soon after infection.”

Profectus BioSciences reports that this is the second phase 1 SBIR grant it has received in the past month.

Previous articleGlenmark Buys Rights to Two mAbs from Chromos
Next articleMechanism for Gene Silencing in Skin Cancer Discovered